Loading...
•
Sep 30, 2020
Protalix Q3 2020 Earnings Report
Protalix reported a decrease in revenue due to timing difference in sales to Brazil, partially offset by increased sales to Pfizer Inc. The company also saw a decrease in revenues from license and R&D services due to completion of phase III clinical trials of PRX-102.
Key Takeaways
Protalix BioTherapeutics reported financial results for the third quarter ended September 30, 2020. The company recorded revenues from selling goods of $3.3 million and revenues from license and R&D services of $7.5 million.
FDA accepted BLA filing of PRX-102 for Fabry disease treatment.
Top-line data from the BRIGHT study expected by end of first quarter, 2021.
Patient treatment period completed for Phase III BRIGHT clinical trial of PRX-102 for Fabry disease.
Launched Expanded Access Program in the United States for PRX-102.
Protalix
Protalix
Protalix Revenue by Segment
Revenue by Segment
License and R&D Services Revenue
CapyFin.com Forward Guidance
Protalix expects to report top-line results from the BRIGHT trial by the end of the first quarter 2021 and anticipates an FDA response to the Type A meeting request during the first week of November 2020.